Related Experiment Video
Updated: Apr 27, 2026
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Factor IXa as a target for anticoagulation in thrombotic disorders and conditions
Dia A Smiley1, Richard C Becker1
1Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Insights
Researchers are developing novel anticoagulants targeting Factor IXa to prevent blood clots without increasing bleeding risk. The ideal anticoagulant would be easily reversible and effective for various thrombotic conditions.
Area of Science:
- Biochemistry and Pharmacology
- Hematology
- Drug Development
Background:
- The development of new anticoagulants is crucial for managing thrombotic disorders like acute coronary syndrome (ACS), atrial fibrillation, and mechanical heart valve thrombosis.
- Current antithrombotic therapies aim for effective coagulation inhibition without inducing excessive bleeding, with a need for easily reversible agents.
- An ideal anticoagulant should possess broad applicability across arterial, venous, and hybrid conditions, and potentially interact with non-biological materials.
Purpose of the Study:
- To review the biochemistry of Factor IXa (FIXa) in the context of thrombotic disorders.
- To explore the evolution of targeted therapies aimed at inhibiting FIXa activity.
- To highlight FIXa as a promising target for developing next-generation anticoagulants.
Main Methods:
- Review of scientific literature on Factor IXa biochemistry and its role in thrombosis.
- Analysis of various therapeutic modalities targeting FIXa, including inhibitors, aptamers, antibodies, and competitive inhibitors.
- Synthesis of information on the development and application of FIXa-targeted antithrombotic agents.
Main Results:
- Factor IXa (FIXa) is a key enzyme in the tissue factor (TF)-mediated coagulation cascade, making it a significant target for antithrombotic drug development.
- Multiple strategies, including small molecule inhibitors, RNA aptamers, monoclonal antibodies, and synthetic inhibitors, have been developed to target FIXa activity.
- The quest for an ideal anticoagulant focuses on achieving effective clot prevention, minimizing bleeding risk, and ensuring rapid reversibility.
Conclusions:
- Factor IXa (FIXa) represents a critical target for developing advanced anticoagulants with improved safety and efficacy profiles.
- Targeting FIXa offers a promising avenue for creating a new generation of antithrombotic therapies for diverse clinical applications.
- The development of easily reversible and broadly applicable anticoagulants remains a key objective in antithrombotic research.
Abstract:
From acute coronary syndrome (ACS) to the prevention of cardioembolic events in patients with atrial fibrillation and thrombosis of mechanical heart valves, there is a quest to develop a new generation of anticoagulants. Perhaps the 'holy grail' of antithrombotic therapy is not only a drug that will prevent coagulation without promoting bleeding but also an anticoagulant that is easily reversible should the clinical need arise. Further, an optimally designed anticoagulant would have broad applications to include arterial, venous, hybrid conditions (atrial flutter and fibrillation) and nonbiological materials. Factor (F)IXa plays a pivotal part in tissue factor (TF)-mediated thrombin generation, and therefore represents a potentially promising target for drug development. FIXa activity has been targeted by multiple modalities, including oral inhibitors, RNA aptamers, monoclonal antibodies and synthetic active-site-blocking competitive inhibitors. Herein, we summarize the biochemistry of FIXa as it applies to thrombotic disorders and conditions, as well as the evolution of targeted therapies.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:16Clot Retraction and Fibrinolysis
01:13Therapeutic Index
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...